{
    "prompt": "\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0009863\nAge: 49\nGender: Female\nSample ID: P-0009863-T01-IM5\nGene Panel: IMPACT410\nCancer Type: Colon Adenocarcinoma\nSample Type: Primary\nTumor Purity: 30.0%\n=============\nDNA Variants:\nATM c.3747-1G>T (p.X1249_splice) - in 9.00% of 192 reads\nBRAF c.1799T>A (p.V600E) - in 18.00% of 455 reads\nCDKN1B c.295_305dup (p.Q104Rfs*19) - in 13.00% of 606 reads\nMAX c.179G>A (p.R60Q) - in 8.00% of 581 reads\nNF2 c.1573A>T (p.K525*) - in 6.00% of 462 reads\nPGR c.44C>T (p.A15V) - in 5.00% of 2276 reads\nRPTOR c.3998G>A (p.R1333H) - in 14.00% of 1399 reads\nTP53 c.876dup (p.G293Rfs*13) - in 14.00% of 1173 reads\nCNA Data:\nAXL - High Level Amplification\nAKT2 - High Level Amplification\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Non-small cell lung cancer\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Capmatinib\",\n    \"Prior Treatment or Resistance Status\": \"N/A\",\n    \"Genomic Features\": \"Somatic variant in gene MET (exon 14 splice site)\",\n    \"FDA-approval status\": \"Approved for adult patients with metastatic NSCLC with MET exon 14 skipping mutation as detected by an FDA-approved test\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf\"\n  }\n}"
}